Aidian Oy

Aidian is a globally operating Finnish developer of pharmaceuticals and diagnostic tests – a builder of well-being. Aidian develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. It is continuously developing new drugs and treatment methods. The core therapy areas of Aidian’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Aidian developes inhaled Easyhaler® pulmonary drugs.

Aidian's customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Consumers with pets are another important customer group.

Aidian's main market is Finland, where it is the clear market leader. Aidian’s products are marketed in over a hundred countries, and the Group's own human pharmaceuticals sales organisation covers almost all key European markets. In other markets Aidian’s products are sold by several collaboration partners. All of Aidian's manufacturing plants and most of its R&D operations are in Finland. Aidian’s headquarters are in Espoo.

Aidian’s A and B shares are listed on Nasdaq Helsinki.